Lucjan Wyrwicz
机构：National Institute of Oncology, Centrum Onkologii · ORCID：0000-0003-0808-6892
发表论文 287 篇 · 总被引 16238 次 · h-index 51
代表论文
- Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer (2025 · New England Journal of Medicine · 被引 265)
- Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study (2025 · Journal of Clinical Oncology · 被引 44)
- Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study (2025 · Journal of Clinical Oncology · 被引 36)
- EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases (2025 · Cancer Treatment Reviews · 被引 20)
- Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study (2025 · Journal of Clinical Oncology · 被引 18)
- Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC). (2025 · Journal of Clinical Oncology · 被引 15)